Publication

HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report.

Authors not recorded

Int J Colorectal Dis2016PMID 26561417stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

cancerMalignant Colorectal Neoplasmcivic_curation1.00
drugCetuximabcivic_curation1.00
drugEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitorcivic_curation1.00
geneHRAScivic_curation1.00
variantHRAS G13Dcivic_curation1.00

Curated evidence

Evidence citing this paper (2)

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
HRAS G13D2
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	—	accepted	EID3852 In an in vitro study, Colo-320, SW48, and CaCO2 cell lines expressing HRAS G13D mutation were associated with resistance to cetuximab treatment, as compared to Colo-320, SW48, and CaCO2 cells expressi… (full text at CIViC) PMID 26561417 · Boidot et al., 2016 · Open in CIViC	civic
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID699 Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanis… (full text at CIViC) PMID 26561417 · Boidot et al., 2016 · Open in CIViC	civic